OnKure Therapeutics
Develops mutation-selective PI3Kα medicines for cancer and vascular anomalies.
Something off on this page? Send us feedback.
Profile
Develops mutation-selective PI3Kα small molecules for cancer and vascular anomalies. Its pipeline centers on OKI-345 for breast cancer and OKI-355 for vascular anomalies; it has no approved products or product-sales revenue.
Develops mutation-selective small molecules for PI3Kα-driven cancers and vascular anomalies. Its named next-generation candidates are OKI-345 for breast cancer and OKI-355 for vascular anomalies, while OKI-219 is no longer planned for independent development.
Structure-based and computational-chemistry-driven design supports small-molecule programs that preferentially target disease-driving mutations while sparing wild-type PI3Kα. The company operates as a clinical-stage biopharmaceutical company, based in Boulder, Colorado, with no approved products or product-sales revenue.
The programs require additional capital before meaningful product revenue can be generated. Clinical progress, regulatory clearance, and continued financing determine whether its programs can reach commercialization.
Company facts
Key statistics
Year to date +28.0% · Average volume (30d) 146.2K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 14, 2026 | Oppenheimer | Reiterate | Outperform | $35 | $14 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | −$0.54 | −$0.31 | +42.1% | $166.7K | — | — | +1.46% |
| May 5, 2026Q1 FY26 | −$0.81 | −$1.11 | −37.0% | $166.7K | — | — | −9.96% |
| Mar 12, 2026Q4 FY25 | −$1.15 | −$0.99 | +13.9% | $16.0M | — | — | +7.39% |
| Nov 6, 2025Q3 FY25 | −$1.20 | −$1.09 | +9.2% | — | — | — | −6.96% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | −$203.0K | $0 | |
| Operating income | −$17.0M | −$16.3M | −$15.5M | −$14.1M | −$15.6M | −$16.9M | |
| Net income | −$15.9M | −$15.4M | −$14.7M | −$13.5M | −$15.2M | −$15.3M | |
| Diluted EPS | −$1.19 | −$1.14 | −$1.09 | −$0.99 | −$1.11 | −$0.31 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $176.4M · Total debt $926.0K · Total assets $179.4M · Shareholders' equity $172.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 40.50M · Float 29.23M · 72.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| RA Capital Management, L.P. | 4.04M | 9.90% | 13G | Apr 7, 2026 |
| AI Biotechnology LLC · 10 percent owner | 4.00M | 9.87% | Form 4 | Apr 7, 2026 |
| Acorn Capital Advisors, LLC | 2.84M | 7.01% | 13F | May 15, 2026 |
| Anders Hove | 2.84M | 22.10% | 13D | May 30, 2025 |
| StepStone Group LP | 2.66M | 6.60% | 13G | Apr 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 22, 2026 | Jason A. Leverone | officer: Chief Financial Officer | −303 | $4.40 |
| Jun 22, 2026 | Nicholas A. Saccomano | director, officer: President and CEO | −86 | $4.40 |
| Mar 23, 2026 | Jason A. Leverone | officer: Chief Financial Officer | −301 | $4.16 |
| Mar 23, 2026 | Nicholas A. Saccomano | director, officer: President and CEO | −86 | $4.16 |
| Dec 22, 2025 | Jason A. Leverone | officer: Chief Financial Officer | −302 | $2.97 |
Peers
- Relay Therapeutics
Pan-mutant PI3Kα programs in breast cancer and vascular anomalies
- Novartis (ADR)
PI3Kα therapy in PIK3CA-mutated breast cancer and PROS
- AstraZeneca (ADR)
AKT therapy for PIK3CA/AKT1/PTEN-altered breast cancer
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| OnKure Therapeutics | $3.79 | 0.00% | $153.5M | — | — | — | — |
| Relay Therapeutics | $19.10 | +1.82% | $4.11B | — | — | 397.4 | −48.3% |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Median | 23.8 | 15.8 | 5.3 | +0.9% |